ProQR Therapeutics (PRQR) Enterprise Value (2014 - 2026)

ProQR Therapeutics has reported Enterprise Value for 15 years, with the latest figure at -$94.9 million in Q1 2026.

• Quarterly Enterprise Value rose 31.83% year-over-year to -$94.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.9 million (up 31.83% YoY) and the FY2025 annual result came in at -$107.6 million, up 32.62% from the prior year.
• Enterprise Value climbed to -$94.9 million in Q1 2026 per PRQR's latest filing, from -$107.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$94.9 million in Q1 2026 and troughed at -$188.8 million in Q1 2022.
• A 5-year average of -$128.2 million and a median of -$128.0 million in 2023 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 54.89% in 2022, down 130.59% in 2022.
• Over 5 years, Enterprise Value stood at -$97.1 million in 2022, then plunged by 31.8% to -$128.0 million in 2023, then declined by 24.77% to -$159.7 million in 2024, then jumped by 32.62% to -$107.6 million in 2025, then rose by 11.74% to -$94.9 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$94.9 million, -$107.6 million, and -$125.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.